Literature DB >> 16505286

Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.

M R Hussein1, D A H Elsers, S A Fadel, A-E M Omar.   

Abstract

BACKGROUND: Although the presence of tumour infiltrating lymphocytes (TIL) is a constant feature in melanomas, their immunophenotypic characterisation is still incomplete. We hypothesise that the transition from normal skin to benign naevi (BN) to melanocytic dysplastic naevi (MDN) to radial growth phase cutaneous malignant melanoma (RGP-CMM) to vertical growth phase cutaneous malignant melanoma (VGP-CMM) is associated with alterations in TIL. This study attempted to test this hypothesis and to characterise TIL in the melanocytic skin lesions.
METHODS: In total, 74 lesions (12 BN, 12 MDN, 13 RGP-CMM, 26 VGP-CMM, and 11 metastatic melanomas) were examined using immunoperoxidase staining methods and antibodies targeting leukocyte common antigen (LCA+), T (CD3+) and B (CD20+) lymphocytes, and resting cytotoxic T cells (TIA-1+).
RESULTS: Histologically, the transitions from normal skin to BN to MDN to RGP-CMM to VGP-CMM was associated with a gradual increase in the numbers of TIL (total, parenchymal, stromal, perivascular, and epidermal TIL, as well as TIL at the base of the lesions). The numbers of TIL were higher at the stroma than at the parenchyma. Similarly, immunostaining revealed that these transitions were associated with a gradual increase in the staining values (staining intensity, percentage of positive cells, and immunoreactivity score) for LCA+, CD20+, CD3+, and TIA-1+cells. The number of CD3+ cells was higher than that of CD20+ cells. All these differences between the normal skin and the lesional ones reached statistical significance (p<0.01). The majority of CD3+ cells were TIA-1+ T cells with cytotoxic potential. Compared with primary melanomas, there was a decrease in TIL in metastatic melanomas.
CONCLUSIONS: The gradual increase in TIL during melanoma tumorigenesis may reflect increased antigenicity of the tumour cells. Although both humoral and cell mediated immunity are involved in melanomagenesis, the latter seems to have the major role. The immune profile of MDN suggests their intermediacy between BN and CMM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505286      PMCID: PMC1860334          DOI: 10.1136/jcp.2005.028860

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  64 in total

1.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors:  C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal:  Arch Surg       Date:  1990-02

2.  Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.

Authors:  F J Tefany; R S Barnetson; G M Halliday; S W McCarthy; W H McCarthy
Journal:  J Invest Dermatol       Date:  1991-08       Impact factor: 8.551

3.  Dysplastic melanocytic nevus. Immunohistochemical heterogeneity by melanosomal markers and S-100.

Authors:  T G Salopek; K Jimbow
Journal:  Am J Dermatopathol       Date:  1991-04       Impact factor: 1.533

4.  Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma.

Authors:  A Kawata; Y Une; M Hosokawa; J Uchino; H Kobayashi
Journal:  Jpn J Clin Oncol       Date:  1992-08       Impact factor: 3.019

5.  The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma.

Authors:  P C Kolbeck; F F Kaveggia; S L Johansson; M T Grune; R J Taylor
Journal:  Mod Pathol       Date:  1992-07       Impact factor: 7.842

6.  The distribution of cellular adhesion molecules in pigmented skin lesions.

Authors:  C M van Duinen; L J van den Broek; B J Vermeer; G J Fleuren; J A Bruijn
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

7.  [Immunohistological analysis of infiltrating lymphocyte subpopulations in gliomas and metastatic brain tumors].

Authors:  T Saito; R Tanaka; M Kouno; N Takai; S Yoshida; N Hara; K Washiyama; K Sekiguchi; T Kumanishi
Journal:  No To Shinkei       Date:  1987-04

8.  Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme.

Authors:  C Clemente; A J Cochran; D E Elder; A Levene; R M MacKie; M C Mihm; F Rilke; N Cascinelli; T B Fitzpatrick; A J Sober
Journal:  Hum Pathol       Date:  1991-04       Impact factor: 3.466

9.  Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.

Authors:  O Azogui; M F Avril; A Margulis; M Guillard; B Caillou; M Prade
Journal:  J Invest Dermatol       Date:  1991-09       Impact factor: 8.551

10.  Correlation of clinical pigmentary characteristics with histopathologically-confirmed dysplastic nevi in nonfamilial melanoma patients. Studies of melanocytic nevi IX.

Authors:  G C Roush; R L Barnhill
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  26 in total

1.  Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Authors:  Francesca M Bosisio; James S Wilmott; Nathalie Volders; Marjorie Mercier; Jasper Wouters; Marguerite Stas; Willeke Am Blokx; Daniela Massi; John F Thompson; Richard A Scolyer; Nicolas van Baren; Joost J van den Oord
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

Review 3.  Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Authors:  Emanuelle M Rizk; Robyn D Gartrell; Luke W Barker; Camden L Esancy; Grace G Finkel; Darius D Bordbar; Yvonne M Saenger
Journal:  Hematol Oncol Clin North Am       Date:  2019-01-17       Impact factor: 3.722

Review 4.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 5.  B cells and antibody production in melanoma.

Authors:  Jessica Da Gama Duarte; Janique M Peyper; Jonathan M Blackburn
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 6.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

7.  Designing vaccines to prevent breast cancer recurrence or invasive disease.

Authors:  Sasha E Stanton; Mary L Disis
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

8.  Immunostimulation and immunoinhibition of premalignant lesions.

Authors:  Richmond T Prehn
Journal:  Theor Biol Med Model       Date:  2007-02-06       Impact factor: 2.432

9.  Phenotypical characteristics of the immune cells in allergic contact dermatitis, atopic dermatitis and pityriasis rosea.

Authors:  Mahmoud Rezk A Hussein; Wafaa M Abdel-Magid; Ramadan Saleh; Essam Nada
Journal:  Pathol Oncol Res       Date:  2008-09-17       Impact factor: 3.201

10.  Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation.

Authors:  Nicole S Anderson; Leslie Turner; Sandra Livingston; Ren Chen; Santo V Nicosia; Patricia A Kruk
Journal:  J Ovarian Res       Date:  2009-10-25       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.